Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

ABBY

(2018) Jeffrey L. Cummings et al.   NEUROLOGY

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

(2018) Lawrence S. Honig et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

(2017) Susanne Ostrowitzki et al.   Alzheimers Research & Therapy

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid

(2016) Tobias Bittner et al.   Alzheimers & Dementia

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

(2016) Eric R. Siemers et al.   Alzheimers & Dementia

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment

(2016) Sepideh Shokouhi et al.   Alzheimers Research & Therapy

Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin

(2016) Mark Ultsch et al.   Scientific Reports

Measurement of Longitudinal  -Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios

(2015) S. M. Landau et al.   JOURNAL OF NUCLEAR MEDICINE

Improved Power for Characterizing Longitudinal Amyloid-  PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region

(2015) K. Chen et al.   JOURNAL OF NUCLEAR MEDICINE

Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction

(2015) Matthias Brendel et al.   NEUROIMAGE

Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics

(2015) Aaron Ritter et al.   Frontiers in Neurology

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

(2012) Henrik Zetterberg   ARCHIVES OF NEUROLOGY

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

Biomarkers in Alzheimer's disease drug development

(2011) Jeffrey L. Cummings   Alzheimers & Dementia

Influence of the training library composition on a patch-based label fusion method: Application to hippocampus segmentation on the ADNI dataset

(2011) Pierrick Coupe et al.   Alzheimers & Dementia

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid β Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease

(2011) Kazunori Uenaka et al.   CLINICAL NEUROPHARMACOLOGY

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

(2011) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

Adding Delayed Recall to the Alzheimer Disease Assessment Scale is Useful in Studies of Mild Cognitive Impairment But Not Alzheimer Disease

(2010) Mary Sano et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Unbiased average age-appropriate atlases for pediatric studies

(2010) Vladimir Fonov et al.   NEUROIMAGE

Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores

(2008) Sid E. O’Bryant   ARCHIVES OF NEUROLOGY